Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
...
Esketamine is indicated in combination with an oral antidepressant for the treatment of treatment-resistant depression in adults. It is also indicated for the treatment of depressive symptoms in adults with major depressive disorder experiencing acute suicidal ideation or behaviour.
Peking University First Hospital, Beijing, Beijing, China
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Tianjin medical university general hospital, Tianjin, China
Tianjin Medical University General Hospital, Tianjin, China
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Tianjin Medical University General Hospital, Tianjin, China
Tianjin Medical University General Hospital, Tianjin, China
Beijing University First Hospital, Beijing, Beijing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.